JBM  Vol.6 No.4 , April 2018
Molecular Targets of Curcumin and Future Therapeutic Role in Leukemia
Abstract: Leukemia is a most prevalent type of cancer around the globe. Due to major side effects of Chemotherapy and radiotherapy, scientists worked to explore the alternative source to treat leukemia. An alternative source for the treatment of leukemia existed in the form of curcumin, a natural phenolic compound extracted from curcuma longa plant. It exhibited anticancer properties reducing the tumor load via apoptosis and cell cycle arrested in various cancer cell lines and controlled tumor proliferation by blocking tumor inducing gene such as FLT3, Akt gene, ROS and NF-κB inhibition. At molecular level, curcumin plays a key therapeutic role in protection of normal cells by up regulation of NRF-2 that induces production of cellular antioxidants. It regulates various signaling pathways including NF-KB, JAK/STAT, PI3K/AKT and JNK pathways, thereby affecting cancer initiation, progression, and metastasis. This review described the potential of curcumin for treatment of leukemia; it affects different signaling cascades and their regulation. This study provides a preclinical foundation for future usage of curcumin in the treatment of cancer.
Cite this paper: Rafiq, S. , Raza, M. , Younas, M. , Naeem, F. , Adeeb, R. , Iqbal, J. , Anwar, P. , Sajid, U. and Manzoor, H. (2018) Molecular Targets of Curcumin and Future Therapeutic Role in Leukemia. Journal of Biosciences and Medicines, 6, 33-50. doi: 10.4236/jbm.2018.64003.

[1]   Busjan, R., et al. (2017) Oral Health Status in Adult Patients with Newly Diagnosed Acute Leukemia. Clinical Oral Investigations, 2017, 1-8.

[2]   Licht, J.D. and Sternberg, D.W. (2005) The Molecular Pathology of Acute Myeloid Leukemia. ASH Education Program Book, 2005, 137-142.

[3]   Kurzrock, R. and Talpaz, M. (1991) The Molecular Pathology of Chronic Myelogenous Leukaemia. British Journal of Haematology, 79, 34-37.

[4]   McNeer, J.L., et al. (2017) Acute Lymphoblastic Leukemia. In: Cancer in Adolescents and Young Adults, Springer, Berlin, 151-175.

[5]   Akintola-Ogunremi, O., et al. (2002) Chronic Lymphocytic Leukemia Presenting with Symptomatic Central Nervous System Involvement. Annals of Hematology, 81, 402-404.

[6]   Gerstung, M., et al. (2017) Precision Oncology for Acute Myeloid Leukemia Using a Knowledge Bank Approach. Nature Genetics, 49, 332-340.

[7]   Phuoc, V., et al. (2016) Bone and Joint Infections in Acute Myelogenous Leukemia: A Retrospective Review of Patients at Mayo Clinic. Open Forum Infectious Diseases, Oxford University Press, Oxford.

[8]   Haguet, H., et al. (2017) Risk of Arterial and Venous Occlusive Events in Chronic Myeloid Leukemia Patients Treated with New Generation BCR-ABL Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Expert Opinion on Drug Safety, 16, 5-12.

[9]   Hanlon, K. and Copland, M. (2017) Chronic Myeloid Leukaemia. Medicine, 45, 287-291.

[10]   Guest, E.M. and Stam, R.W. (2017) Updates in the Biology and Therapy for Infant Acute Lymphoblastic Leukemia. Current Opinion in Pediatrics, 29, 20-26.

[11]   Glavey, S., et al. (2017) Emergence of Bruton’s Tyrosine Kinase-Negative Hodgkin Lymphoma during Ibrutinib Treatment of Chronic Lymphocytic Leukaemia. European Journal of Haematology, 99, 378-380.

[12]   Goede, V., et al. (2014) Obinutuzumab Plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 370, 1101-1110.

[13]   Khaled, S., Al Malki, M. and Marcucci, G. (2016) Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights. Oncology, 30, 318-318.

[14]   Siegel, R., et al. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.

[15]   Socinski, M., et al. (2004) Combined Modality Trials of the Cancer and Leukemia Group B in Stage III Non-Small-Cell Lung Cancer: Analysis of Factors Influencing Survival and Toxicity. Annals of Oncology, 15, 1033-1041.

[16]   Meng, C.Y., et al. (2013) Cytogenetic Profile of de Novo Acute Myeloid Leukemia Patients in Malaysia. International Journal of Biomedical Science: IJBS, 9, 26-32.

[17]   Abu-Elmagd, M., et al. (2015) Individualized Medicine Enabled by Genomics in Saudi Arabia. BMC Medical Genomics, 8, S3.

[18]   Badar, F., et al. (2016) Epidemiology of Cancers in Lahore, Pakistan, 2010-2012: A Cross-Sectional Study. BMJ Open, 6, e011828.

[19]   Yang, H., et al. (2017) Preclinical Activity of FF-10501-01, a Novel Inosine-5-monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. Leukemia Research, 59, 85-92.

[20]   Robak, T. (2012) Rituximab for Chronic Lymphocytic Leukemia. Expert Opinion on Biological Therapy, 12, 503-515.

[21]   Pasic, I. and Lipton, J.H. (2017) Current Approach to the Treatment of Chronic Myeloid Leukaemia. Leukemia Research, 55, 65-78.

[22]   Basha, R., et al. (2014) Targeted Nanoparticles for Pediatric Leukemia Therapy. Frontiers in Oncology, 4, 101.

[23]   Pépin, A., et al. (2016) Adverse Neuropsychological Effects Associated with Cumulative Doses of Corticosteroids to Treat Childhood Acute Lymphoblastic Leukemia: A Literature Review. Critical Reviews in Oncology/Hematology, 107, 138-148.

[24]   Gupta, S.C., et al. (2012) Discovery of Curcumin, a Component of Golden Spice, and Its Miraculous Biological Activities. Clinical and Experimental Pharmacology and Physiology, 39, 283-299.

[25]   Gibson-Moore, H. and Spiro, A. (2017) Can Turmeric Really Prevent Cancer? Nutrition Bulletin, 42, 141-147.

[26]   Kocaadam, B. and Sanlier, N. (2017) Curcumin, an Active Component of Turmeric (Curcuma longa), and Its Effects on Health. Critical Reviews in Food Science and Nutrition, 57, 2889-2895.

[27]   Shanmugam, M.K., et al. (2015) The Multifaceted Role of Curcumin in Cancer Prevention and Treatment. Molecules, 20, 2728-2769.

[28]   Caka, M., et al. (2017) Controlled Release of Curcumin from Poly (HEMA-MAPA) Membrane. Artificial Cells, Nanomedicine, and Biotechnology, 45, 426-431.

[29]   Qadir, M.I., Naqvi, S.T.Q. and Muhammad, S.A. (2016) Curcumin: A Polyphenol with Molecular Targets for Cancer Control. Asian Pacific Journal of Cancer Prevention, 17, 2735-2739.

[30]   Kasi, P.D., et al. (2016) Molecular Targets of Curcumin for Cancer Therapy: An Updated Review. Tumor Biology, 37, 13017-13028.

[31]   Kelkel, M., et al. (2010) Potential of the Dietary Antioxidants Resveratrol and Curcumin in Prevention and Treatment of Hematologic Malignancies. Molecules, 15, 7035-7074.

[32]   László Hackler Jr., B.ó., Gyuris, M., Sipos, P., Fábián, G., Molnár, E., Marton, A., Faragó, N., Mihály, J., Nagy, L.I., Szénási, T., Diron, A., Párducz, á., Kanizsai, I. and Puskás, L.G. (2016) The Curcumin Analog C-150, Influencing NF-κB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity in Vitro and in Vivo. PLoS ONE, 11, e0149832.

[33]   Wilken, R., Veena, M.S., Wang, M.B. and Srivatsan, E.S. (2011) Curcumin: A Review of Anti-Cancer Properties and Therapeutic Activity in Head and Neck Squamous Cell Carcinoma. Molecular Cancer, 10, 12.

[34]   Fresco, P., et al. (2010) The Anticancer Properties of Dietary Polyphenols and Its Relation with Apoptosis. Current Pharmaceutical Design, 16, 114-134.

[35]   Anuchapreeda, S., et al. (2006) The Cytotoxic Effect of Curumin, Demethoxycurcumin and Bisdemethoxycurcumin Purified from Turmeric Powder on Leukemic Cell Lines. Journal of Associated Medical Sciences, 39, 60-71.

[36]   Aggarwal, B.B. and Sung, B. (2009) Pharmacological Basis for the Role of Curcumin in Chronic Diseases: An Age-Old Spice with Modern Targets. Trends in Pharmacological Sciences, 30, 85-94.

[37]   Yu, J., et al. (2013) Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia. PLoS ONE, 8, e55934.

[38]   Grafone, T., et al. (2012) An Overview on the Role of FLT3-Tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment. Oncology Reviews, 6, e8.

[39]   Ghalaut, V.S., et al. (2012) Effect of Imatinib Therapy with and without Turmeric Powder on Nitric Oxide Levels in Chronic Myeloid Leukemia. Journal of Oncology Pharmacy Practice, 18, 186-190.

[40]   Sa, G. and Das, T. (2008) Anti Cancer Effects of Curcumin: Cycle of Life and Death. Cell Division, 3, 14.

[41]   Chen, J., Wang, F.-L. and Chen, W.-D. (2014) Modulation of Apoptosis-Related Cell Signalling Pathways by Curcumin as a Strategy to Inhibit Tumor Progression. Molecular Biology Reports, 41, 4583-4594.

[42]   Aggarwal, B.B. (2010) Targeting Inflammation-Induced Obesity and Metabolic Diseases by Curcumin and Other Nutraceuticals. Annual Review of Nutrition, 30, 173-199.

[43]   Ambuj Kumar, V.R., Sethumadhavan, R. and Purohit, R. (2013) AKT Kinase Pathway: A Leading Target in Cancer Research. The Scientific World Journal, 2013, Article ID: 756134.

[44]   Altomare, D.A. and Testa, J.R. (2005) Perturbations of the AKT Signaling Pathway in Human Cancer. Oncogene, 24, 7455-7464.

[45]   Wang, J. and Yi, J. (2008) Cancer Cell Killing via ROS: To Increase or Decrease, That Is the Question. Cancer Biology & Therapy, 7, 1875-1884.

[46]   Gopal, P.K., Paul, M. and Paul, S. (2014) Curcumin Induces Caspase Mediated Apoptosis in JURKAT Cells by Disrupting the Redox Balance. Asian Pacific Journal of Cancer Prevention, 15, 93-100.

[47]   Guo, Y., et al. (2014) Curcumin Induces Apoptosis via Simultaneously Targeting AKT/mTOR and RAF/MEK/ERK Survival Signaling Pathways in Human Leukemia THP-1 Cells. Die Pharmazie—An International Journal of Pharmaceutical Sciences, 69, 229-233.

[48]   Thayyullathil, F., et al. (2008) Rapid Reactive Oxygen Species (ROS) Generation Induced by Curcumin Leads to Caspase-Dependent and -Independent Apoptosis in L929 Cells. Free Radical Biology and Medicine, 45, 1403-1412.

[49]   Hail Jr., N. (2008) Mitochondrial Reactive Oxygen Species Affect Sensitivity to Curcumin-Induced Apoptosis. Free Radical Biology and Medicine, 44, 1382-1393.

[50]   Zhou, D., Shao, L. and Spitz, D.R. (2014) Reactive Oxygen Species in Normal and Tumor Stem Cells. Advances in Cancer Research, 122, 1-67.

[51]   Pulido-Moran, M., Moreno-Fernandez, J. and Ramirez-Tortosa, C. (2016) Curcumin and Health. Molecules, 21, 264.

[52]   Zheng, R., You, Z., Jia, J., Lin, S., Han, S., Liu, A., Long, H. and Wang, S. (2016) Curcumin Enhances the Antitumor Effect of ABT-737 via Activation of the ROS-ASK1-JNK Pathway in Hepatocellular Carcinoma Cells. Molecular Medicine Reports, 13, 1570-1576.

[53]   Susana González-Reyes, S.G.-B., Medina-Campos, O.N. and Pedraza-Chaverri, J. (2013) Curcumin Pretreatment Induces Nrf2 and an Antioxidant Response and Prevents Hemin-Induced Toxicity in Primary Cultures of Cerebellar Granule Neurons of Rats. Oxidative Medicine and Cellular Longevity, 2013, Article ID: 801418.

[54]   Fan, Z., Duan, X., Cai, H., Wang, L., Li, M., Qu, J., Li, W., Wang, Y. and Wang, J. (2015) Curcumin Inhibits the Invasion of Lung Cancer Cells by Modulating the PKCα/Nox-2/ROS/ATF-2/MMP-9 Signaling Pathway. Oncology Reports, 34, 691-698.

[55]   Zheng, J., K.C., Yang, X., Cui, X., Lin, X. and Zhang, Z. (2017) Protein Kinase C-α (PKCα) Modulates Cell Apoptosis by Stimulating Nuclear Translocation of NF-Kappa-B p65 in Urothelial Cell Carcinoma of the Bladder. BMC Cancer, 17, 432.

[56]   Olivera, A., Moore, T.W., Hu, F., Brown, A.P., Sun, A., Liotta, D.C., Snyder, J.P., Yoon, Y., Shim, H., Marcus, A.I., Miller, A.H. and Pace, T.W. (2012) Inhibition of the NF-κB Signaling Pathway by the Curcumin Analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): Anti-Inflammatory and An-ti-Cancer Properties. International Immunopharmacology, 12, 368-377.

[57]   Aggarwal, B.B., Surh, Y.-J. and Shishodia, S. (2007) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Vol. 595, Springer Science & Business Media, Berlin.

[58]   Kumar, G., et al. (2016) Molecular Mechanisms Underlying Chemopreventive Potential of Curcumin: Current Challenges and Future Perspectives. Life Sciences, 148, 313-328.

[59]   Tuorkey, M. (2014) Curcumin a Potent Cancer Preventive Agent: Mechanisms of Cancer Cell Killing. Interventional Medicine and Applied Science, 6, 139-146.

[60]   Kuttan, G., et al. (2007) Antitumor, Anti-Invasion, and Antimetastatic Effects of Curcumin. In: Aggarwal, B.B., Surh, Y.-J. and Shishodia, S., Eds., The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, Springer, Berlin, 173-184.

[61]   Aggarwal, S., et al. (2006) Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation. Molecular Pharmacology, 69, 195-206.

[62]   Das, L. and Vinayak, M. (2014) Long-Term Effect of Curcumin Down-Regulates Expression of Tumor Necrosis Factor-α and Interleukin-6 via Modulation of E26 Transformation-Specific Protein and Nuclear Factor-κB Transcription Factors in Livers of Lymphoma Bearing Mice. Leukemia & Lymphoma, 55, 2627-2636.

[63]   Tima, S., et al. (2017) Stable Curcumin-Loaded Polymeric Micellar Formulation for Enhancing Cellular Uptake and Cytotoxicity to FLT3 Overexpressing EoL-1 Leukemic Cells. European Journal of Pharmaceutics and Biopharmaceutics, 114, 57-68.

[64]   Metts, J., et al. (2017) Imipramine Blue Sensitively and Selectively Targets FLT3-ITD Positive Acute Myeloid Leukemia Cells. Scientific Reports, 7, Article No. 4447.

[65]   Tima, S., et al. (2016) Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells. Journal of Pharmaceutical Sciences, 105, 3645-3657.

[66]   Hsu, C.-H. and Cheng, A.-L. (2007) Clinical Studies with Curcumin. In: The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, Springer, Berlin, 471-480.

[67]   Shanbhag, V.K.L. (2017) Curcumin in Chronic Lymphocytic Leukemia—A Review. Asian Pacific Journal of Tropical Biomedicine, 7, 549-554.

[68]   Pulido-Moran, M., et al. (2016) Curcumin and Health. Molecules, 21, 264.